EHC 2022 | Preliminary data on the use of anti-CGRP mAbs in pediatric migraine

Influencing CGRP pathways is nowadays one of the main mechanisms to treat migraine. Several clinical trials have supported the use of anti-CGRP monoclonal antibodies in adults. However, little is known about these drugs in children and adolescents with migraine. Massimiliano Valeriani, MD, PhD, Hospital Bambino Gesù, Rome, Italy, discusses the preliminary findings of a Phase III, randomized, double-blind, placebo-controlled study evaluating the use of anti-CGRP monoclonal antibodies in pediatric migraine. To date, the first data evaluations confirm what has been shown in the adult population. However, more pediatric studies will be needed to substantiate these preliminary results. This interview took place at the 16th European Headache Congress (EHC) in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.